Interim Reports
Interim Report 2008
Highlights
- Positive results from our first Phase I study.
- First commercial exclusive evaluation agreement with a major consumer healthcare company.
- Strengthening prospects for further licensing and joint development agreements with other healthcare and dermatological companies.
- Expanding library of compounds and combinations of compounds.
- Growing intellectual property portfolio with three granted patents and 12 patent applications.
Interim Report 2007
Highlights
- MHRA approval to conduct first Phase I clinical trial.
- Clinical Research Organisation appointed.
- Formulations of other compounds initiated for further human use studies.
- Compound library now contains over 1,000 compounds for screening.
- Growing patent portfolio which is continually being evaluated.
- Cash balance at 31 January 2007 of £2.5 million (31 January 2006: £323,000).
- Tight overhead cost control.
- Development programme costs in line with budget.
Recent News
06/08/2008 13:13
Syntopix proposal to raise £1.5million passed by shareholders...
03/07/2008 07:00
Syntopix enters into joint development agreement with Procter & Gamble...
25/02/2008 07:00
Syntopix announces positive results from its Phase II cosmetic study...